Newsitem on Gold Anchor

Groundbraking publication on randomized trial on ultra-hypofractionated radiotherapy, the HYPO-RT-PC phase 3! Fiducial markers will become even more important when applying ultra-hypofractionated radiotherapy for prostate cancer.

Congratulations to all the 12 Swedish and Danish centers that have contributed to the HYPO-RT-PC phase 3 trial!

As the first published randomized trial on ultra-hypofractionated radiotherapy for prostate cancer, Lancet 18 2019, this groundbreaking study with 1,200 patients will lead to an increased use of ultra-hypofractionation.  Fiducial markers play a key role in this development. To find out why, see GoldAnchorMarker.com.